Literature DB >> 16249382

An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.

Judith Staerk1, Catherine Lacout, Takeshi Sato, Steven O Smith, William Vainchenker, Stefan N Constantinescu.   

Abstract

Ligand binding to the thrombopoietin receptor (TpoR) is thought to impose a dimeric receptor conformation(s) leading to hematopoietic stem cell renewal, megakaryocyte differentiation, and platelet formation. Unlike other cytokine receptors, such as the erythropoietin receptor, TpoR contains an amphipathic KWQFP motif at the junction between the transmembrane (TM) and cytoplasmic domains. We show here that a mutant TpoR (delta5TpoR), where this sequence was deleted, is constitutively active. In the absence of ligand, delta5TpoR activates Jak2, Tyk2, STAT5, and mitogen-activated protein (MAP) kinase, but does not appear to induce STAT3 phosphorylation. Delta5TpoR induces hematopoietic myeloid differentiation in the absence of Tpo. In the presence of Tpo, the delta5TpoR mutant appears to enhance erythroid differentiation when compared with the Tpo-activated wild-type TpoR. Strikingly, individual substitution of K507 or W508 to alanine also induces constitutive TpoR activation, indicating that the K and W residues within the amphipathic KWQFP motif are crucial for maintaining the unliganded receptor inactive. These residues may be targets for activating mutations in humans. Such a motif may exist in other receptors to prevent ligand-independent activation and to allow signaling via multiple flexible interfaces.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16249382      PMCID: PMC1379661          DOI: 10.1182/blood-2005-06-2600

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Helix packing and orientation in the transmembrane dimer of gp55-P of the spleen focus forming virus.

Authors:  Wei Liu; Evan Crocker; Stefan N Constantinescu; Steven O Smith
Journal:  Biophys J       Date:  2005-05-13       Impact factor: 4.033

2.  The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely oriented, hydrophobic motif.

Authors:  S N Constantinescu; L J Huang; H Nam; H F Lodish
Journal:  Mol Cell       Date:  2001-02       Impact factor: 17.970

3.  Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization.

Authors:  R E Richard; B Wood; H Zeng; L Jin; T Papayannopoulou; C A Blau
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

4.  Generation of mammalian cells stably expressing multiple genes at predetermined levels.

Authors:  X Liu; S N Constantinescu; Y Sun; J S Bogan; D Hirsch; R A Weinberg; H F Lodish
Journal:  Anal Biochem       Date:  2000-04-10       Impact factor: 3.365

5.  Analysis of Tyr to Phe and fa/fa leptin receptor mutations in the PC12 cell line.

Authors:  S Eyckerman; W Waelput; A Verhee; D Broekaert; J Vandekerckhove; J Tavernier
Journal:  Eur Cytokine Netw       Date:  1999-12       Impact factor: 2.737

6.  A cellular reporter assay to monitor insulin receptor kinase activity based on STAT 5-dependent luciferase gene expression.

Authors:  P Storz; H Döppler; J Horn-Müller; B Groner; K Pfizenmaier; G Müller
Journal:  Anal Biochem       Date:  1999-12-01       Impact factor: 3.365

7.  The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor.

Authors:  L J Huang; S N Constantinescu; H F Lodish
Journal:  Mol Cell       Date:  2001-12       Impact factor: 17.970

8.  The cytoplasmic domain of Mpl receptor transduces exclusive signals in embryonic and fetal hematopoietic cells.

Authors:  Cécile Challier; Laurence Cocault; Rolande Berthier; Nadine Binart; Isabelle Dusanter-Fourt; Georges Uzan; Michèle Souyri
Journal:  Blood       Date:  2002-09-15       Impact factor: 22.113

9.  Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer.

Authors:  Nadine Seubert; Yohan Royer; Judith Staerk; Katharina F Kubatzky; Virginie Moucadel; Shyam Krishnakumar; Steven O Smith; Stefan N Constantinescu
Journal:  Mol Cell       Date:  2003-11       Impact factor: 17.970

10.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice.

Authors:  Hédia Chagraoui; Emiko Komura; Micheline Tulliez; Stéphane Giraudier; William Vainchenker; Françoise Wendling
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

View more
  51 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 2.  What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?

Authors:  Paola Guglielmelli; Giada Rotunno; Annalisa Pacilli; Alessandro Maria Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 3.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

Review 4.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

5.  Two rare MPL gene mutations in patients with essential thrombocythemia.

Authors:  Haruhiko Ohashi; Kayoko Arita; Shoko Fukami; Kayo Oguri; Hirokazu Nagai; Toshiya Yokozawa; Tomomitsu Hotta; Shuichi Hanada
Journal:  Int J Hematol       Date:  2009-09-02       Impact factor: 2.490

Review 6.  Molecular aspects of myeloproliferative neoplasms.

Authors:  François Delhommeau; Dorota Jeziorowska; Christophe Marzac; Nicole Casadevall
Journal:  Int J Hematol       Date:  2010-02-27       Impact factor: 2.490

7.  Orientation-specific signalling by thrombopoietin receptor dimers.

Authors:  Judith Staerk; Jean-Philippe Defour; Christian Pecquet; Emilie Leroy; Hélène Antoine-Poirel; Ian Brett; Miki Itaya; Steven O Smith; William Vainchenker; Stefan N Constantinescu
Journal:  EMBO J       Date:  2011-09-02       Impact factor: 11.598

Review 8.  Molecular classification of myeloproliferative neoplasms-pros and cons.

Authors:  Moosa Qureshi; Claire Harrison
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

9.  A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction.

Authors:  Alessandro Pancrazzi; Paola Guglielmelli; Vanessa Ponziani; Gaetano Bergamaschi; Alberto Bosi; Giovanni Barosi; Alessandro M Vannucchi
Journal:  J Mol Diagn       Date:  2008-07-31       Impact factor: 5.568

10.  An ENU-induced recessive mutation in Mpl leads to thrombocytopenia with overdominance.

Authors:  E Ricky Chan; Heather Lavender; Geqiang Li; Peter Haviernik; Kevin D Bunting; Mark D Adams
Journal:  Exp Hematol       Date:  2008-12-06       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.